Speaker
Dr
Kohshin Washiyama
(Advanced Clinical Research Center, Fukushima Medical University)
Summary
Radiotheranostics — the integrated use of radionuclides for both diagnosis and therapy — is rapidly advancing within the medical field. Establishing a robust radionuclide supply chain and ensuring a stable isotope supply are essential for the long-term sustainability of this modality. Among promising candidates, astatine-211 (211At) is an alpha-emitting radionuclide producible via cyclotron irradiation and has gained global attention for its therapeutic potential. In Japan, the Japan Astatine Community (JAC), comprising universities, research institutes, and industry partners, is driving the research, development, and clinical translation of 211At through collaborative information exchange and organized community activities.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
Author
Dr
Kohshin Washiyama
(Advanced Clinical Research Center, Fukushima Medical University)
Co-authors
Dr
Hiroki Kanda
(Research Center for Nuclear Physics, The University of Osaka)
Mr
Kazuya Taki
(Sumitomo Heavy Industries, Ltd.)
Prof.
Mikako Ogawa
(Graduate School of Pharmaceutical Sciences, Hokkaido University)
Prof.
Takashi Nakano
(Research Center for Nuclear Physics, The University of Osaka)
